ENvue Medical received Nasdaq staff delisting determination for minimum bid price violation
On July 10, 2026, ENvue Medical received a Staff Determination Letter from Nasdaq notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days (May 26 through July 8, 2026), violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-calendar day compliance period because it effected a 1-for-10 reverse stock split on August 12, 2025. ENvue intends to request a hearing before the Nasdaq Panel to appeal the determination; a timely request will stay any suspension or delisting action pending the Panel's decision.
Key facts
- Closing bid price below $1.00 per share for 30 consecutive business days from May 26, 2026 through July 8, 2026
- Company ineligible for standard 180-calendar day compliance period due to prior 1-for-10 reverse stock split on August 12, 2025
- Company intends to request hearing before Nasdaq Panel to appeal Staff determination
- Timely hearing request will stay suspension or delisting action pending Panel decision
Why it matters
ENvue faces a delisting determination with no automatic compliance cure period available; the company's continued Nasdaq listing now depends entirely on the outcome of a Panel hearing appeal, creating material uncertainty about its public market access.
Developing story
- NT 10-Q
- 8-Kthis filing
Share
Derived from 8-K filed 2026-07-10. Not investment advice. View the source filing on SEC.gov →